Filament Health Corp. (FLHLF)

Market Cap	26.18K -99.7%
Revenue (ttm)	329.20K -78.7%
Net Income	-2.95M
EPS	-0.01
Shares Out	261.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,000
Average Volume	47,282
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.0000 - 0.0399
Beta	0.76
RSI	31.31
Earnings Date	Mar 31, 2026

About Filament Health

Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company’s leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, the company provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is h...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Benjamin Lightburn
• Employees: 13
• Stock Exchange: OTCMKTS
• Ticker Symbol: FLHLF

Financial Performance

In 2024, Filament Health's revenue was 616,678, a decrease of -71.06% compared to the previous year's 2.13 million. Losses were -4.97 million, -6.61% less than in 2023.

Financial numbers in CAD